海南海藥(000566.SZ):控股子公司收到藥品生產企業GMP認證檢查結果
格隆匯 8 月 26日丨海南海藥(000566.SZ)公佈,公司控股子公司重慶天地藥業有限責任公司(“天地藥業”)於近日收到重慶市藥品監督管理局核准簽發的《關於藥品生產企業GMP 認證檢查結果的通知》(編號:GMP 20200007號),具體內容如下:
企業名稱:重慶天地藥業有限責任公司
生產地址:重慶市忠縣忠州大道瀋陽路1號
認證範圍:無菌原料藥(頭孢孟多酯鈉、頭孢噻吩鈉、美羅培南)
結論:經檢查,公司GMP 認證申請符合《藥品生產質量管理規範》的有關規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.